News Releases
-
Ryvu Therapeutics Reports 2024 Q3 Financial Results and Provides Corporate Update
-
Ryvu Therapeutics to Collaborate with nCage Therapeutics on the Development of a Next-Generation ADC Platform
-
Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
What we do
We challenge current treatment paradigms
At Ryvu, we develop therapeutics that address clinical limitations of current treatments in oncology.
Our pipeline includes candidates with differentiated properties from kinase, synthetic lethality, and immuno-oncology programs.
Investor Relations
Ryvu Therapeutics (Selvita Oncology) was founded in 2007. Since 2014, the company has been listed on Warsaw Stock Exchange under the ticker RVU.
Ryvu Therapeutics is organized for highly efficient R&D driven by breakthrough science, aiming to realize full value potential for its shareholders, partners and employees.
See More
49.50 PLN
+3.13%
RVU • 04/12/2024 15:23 • Warsaw Stock Exchange